Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38

TY - JOUR

T1 - Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38

AU - Lal, Aroon S.

AU - Clifton, Andrew D.

AU - Rouse, John

AU - Segal, Anthony W.

AU - Cohen, Philip

PY - 1999/6/7

Y1 - 1999/6/7

N2 - Activation of the neutrophil NADPH oxidase by either the bacterial peptide fMLP or phorbol myristate acetate (PMA) is partially suppressed by SB 203580, a specific inhibitor of the MAP kinase family member, SAPK2/p38. The concentration of SB 203580 that suppresses activation of NADPH oxidase is similar to that which inhibits SAPK2/p38 in vitro, and both fMLP and PMA induce an extremely rapid and potent activation of SAPK2/p38 in neutrophils. SB 203580 does not exert its effect by preventing the neutrophil priming reaction, by suppressing the phosphorylation of p47(phax), or by preventing the translocation of p47(phax)/67(phax) to the plasma membrane.

AB - Activation of the neutrophil NADPH oxidase by either the bacterial peptide fMLP or phorbol myristate acetate (PMA) is partially suppressed by SB 203580, a specific inhibitor of the MAP kinase family member, SAPK2/p38. The concentration of SB 203580 that suppresses activation of NADPH oxidase is similar to that which inhibits SAPK2/p38 in vitro, and both fMLP and PMA induce an extremely rapid and potent activation of SAPK2/p38 in neutrophils. SB 203580 does not exert its effect by preventing the neutrophil priming reaction, by suppressing the phosphorylation of p47(phax), or by preventing the translocation of p47(phax)/67(phax) to the plasma membrane.

UR - https://www.scopus.com/pages/publications/0033532509

U2 - 10.1006/bbrc.1999.0759

DO - 10.1006/bbrc.1999.0759

M3 - Article

C2 - 10362531

AN - SCOPUS:0033532509

SN - 0006-291X

VL - 259

SP - 465

EP - 470

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 2

ER -